JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

2.45 1.24

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.45

Max

2.49

Galvenie mērījumi
By Trading Economics
Ienākumi	672K -877K
EPS	-0.24
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	671K -877K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.4M 9.5M
Iepriekšējā atvēršanas cena	1.21
Iepriekšējā slēgšanas cena	2.45

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. febr. 23:57 UTC

Tirgus saruna

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

2026. g. 8. febr. 23:47 UTC

Tirgus saruna

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

2026. g. 8. febr. 23:43 UTC

Tirgus saruna

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

2026. g. 8. febr. 23:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. febr. 23:34 UTC

Tirgus saruna

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

2026. g. 8. febr. 23:26 UTC

Tirgus saruna

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

2026. g. 8. febr. 22:55 UTC

Peļņas

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

2026. g. 8. febr. 21:43 UTC

Tirgus saruna

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

2026. g. 8. febr. 21:16 UTC

Tirgus saruna

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

2026. g. 8. febr. 21:15 UTC

Tirgus saruna

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

2026. g. 7. febr. 09:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 7. febr. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 7. febr. 05:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. febr. 02:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Money, High Anxiety -- Barrons.com

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 6. febr. 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026. g. 6. febr. 21:22 UTC

Tirgus saruna

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026. g. 6. febr. 21:17 UTC

Peļņas

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026. g. 6. febr. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. febr. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026. g. 6. febr. 21:13 UTC

Peļņas

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026. g. 6. febr. 21:13 UTC

Peļņas

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026. g. 6. febr. 21:04 UTC

Tirgus saruna

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026. g. 6. febr. 20:34 UTC

Peļņas

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.